Cardiff Oncology, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(in thousands, except per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Royalty revenues | $593 | $683 |
| Costs and expenses: | ||
| Research and development | 35,329 | 36,852 |
| Selling, general and administrative | 14,224 | 12,482 |
| Total operating expenses | 49,553 | 49,334 |
| Loss from operations | (48,960) | (48,651) |
| Other income (expense), net: | ||
| Interest income | 3,104 | 3,259 |
| Other income (expense), net | 5 | (39) |
| Total other income (expense), net | 3,109 | 3,220 |
| Net loss | (45,851) | (45,431) |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | (25) | (24) |
| Net loss attributable to common stockholders | $(45,876) | $(45,455) |
| Net loss per common share — basic and diluted | $(0.69) | $(0.95) |
| Weighted-average shares outstanding — basic and diluted | 66,841 | 47,650 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.